Dose-sparing AI vaccine supports global supply
A potentially dose-sparing vaccine, developed by a Chinese-British
team, could be crucial for building a global supply of avian influenza vaccine
in the case of a pandemic.
The vaccine containing inactivated whole particles of the virulent H5N1 avian
strain evoked good immune responses at low doses in early clinical
trials, the researchers found.
The vaccine was safe, and was most effective at eliciting virus-specific
antibodies if given in two doses with aluminum hydroxide adjuvant four weeks
apart, reported Jiangtao Lin and colleagues of the Chinese-Japanese Friendship
Hospital in Beijing.
"These findings identify a potential dose-sparing approach that could be
crucial for a global supply of pandemic vaccine," said Iain Stephenson of the
Leicester Royal Infirmary, in England.
Foreseeing a shortage of vaccine should the pandemic H5N1 strain of avian flu
leap from birds to humans, the World
has advocated investigations into dose-sparing strategies, such
as the use of whole-virion vaccine and adjuvants.
The researchers say that the best approach to vaccinating against AI may be
one that combines the powerful immunogenicity of a whole inactivated virus with
The whole virion approach also preserves the estimated 20% to 30% of antigens
typically lost during the split-vaccine manufacturing process, thereby making
more vaccine available.
"Our trial suggests that an H5N1 vaccine manufactured and formulated with
both of these approaches is well tolerated and immunogenic," they said.
To comment, login here
Or register to be able to comment.